Avalon GloboCare Receives Notice of Allowance for Groundbreaking CAR-T and CAR-NK Cell Technology in China

Core Insights - Avalon GloboCare Corp. has received a Notice of Allowance from the China National Intellectual Property Administration for its patent application AVAR1901CN, marking a significant step in expanding its intellectual property into China and enhancing its global market position [1][2]. Group 1: Patent and Technology - The AVAR1901CN patent, co-developed with Arbele Limited, focuses on innovative technology aimed at improving the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-Natural Killer (NK) cells [2][3]. - The bispecific anti-CD19xCD22 CAR targets both CD19 and CD22 antigens, which reduces the risk of tumor escape due to antigen loss [3][7]. - The technology induces a localized cytokine response, activating cytokines only upon tumor cell engagement, thereby enhancing CAR cell cytotoxicity, survival, and proliferation while stimulating a host anti-tumor immune response [3][7]. Group 2: Company Overview - Avalon GloboCare Corp. is dedicated to developing and delivering innovative precision diagnostics and clinical laboratory services, aiming to establish a leading role in diagnostic testing innovation [4]. - The company utilizes proprietary technology to provide precise, genetics-driven results and offers a broad portfolio of diagnostic tests, including drug testing and toxicology [4].